Top

BMC Pregnancy and Childbirth

Published in:

Open Access 01-12-2020 | ICSI | Research article

Prognostic role of follicular fluid tumor necrosis factor alpha in the risk of early ovarian hyperstimulation syndrome

Authors: Miaad Jabbar Alhilali, Abbas Parham, Armin Attaranzadeh, Malihe Amirian, Mohammad Azizzadeh

Published in: BMC Pregnancy and Childbirth | Issue 1/2020

Abstract

Background

Ovarian hyperstimulation syndrome (OHSS) is an iatrogenic condition characterized by capillary hyperpermeability which can be predicted by preovulatory ovarian responses such as number of follicles. A variety of cytokines are thought to be involved in pathophysiology of this syndrome.

Methods

A prospective cohort study invloving sixty intracytoplasmic sperm injection (ICSI) patients. On the day of hCG injection, we explored the threshold of larger follicles ≥11 mm diameter with a count of ≥18 follicles for the high-risk moderate-to-severe OHSS and 13–18 follicles for the low-risk moderate-to-severe OHSS. Whereas larger follicles count of less than 13 were classified as normoresponders. Pooled follicular fluid (FF) samples of each patient were collected on the day of oocyte retrieval. Magnetic multiplex immunoassay was explored to measure the concentrations of some intrafollicular cytokines including: GM-CSF, INF-γ, TNF-α, IL-10, CXCL8/IL-8, IL-6, IL-5, IL-4, IL-2, and IL-1β. All sixty patients underwent controlled ovarian hyperstimulation (COH) with either GnRH agonist or antagonist protocols.

Results

Intrafollicular TNF-α concentration was significantly different (p < 0.05) in the high-risk moderate-to-severe OHSS patients compared to low-risk moderate-to-severe OHSS patients and normoresponders. TNF-α in FF had a negative correlation with the chance of high-risk moderate-to-severe OHSS. The differences in the risk of OHSS between patients who received GnRH agonist or antagonist were not significant (p > 0.05).

Conclusions

In accordance to the negative correlation of TNF-α and high risk of early OHSS, we did not expect TNF-α to play a role in increasing vascular permeability in ovarian tissues. In addition, the risk of early moderate-to-severe OHSS was not affected by different GnRH superovulation protocols.

Alper MM, Smith LP, Sills ES. Ovarian hyperstimulation syndrome: current views on pathophysiology, risk factors, prevention, and management. J Experi Clinic Assist Reprod. 2009;6:3.

Ashrafi M, Bahmanabadi A, Akhond M, Arabipoor A. Predictive factors of early moderate/severe ovarian hyperstimulation syndrome in non-polycystic ovarian syndrome patients: a statistical model. Arch Gynecol Obstet. 2015. https://doi.org/10.1007/s00404-015-3723-0.

Mathur RS, Severe OHSS. Patients should be allowed to weigh the morbidity of OHSS against benefits of parenthood. Hum Reprod. 1997:2183–5.

Mathur RS, Jenjkins JM, Bansal AS. The possible role of the immune system in the aetiopathogenesis of ovarian hyperstimulation syndrome. Hum Reprod. 1997;12(12):2629–4.CrossRef

Elchalal U, Schenker JG. The pathophysiology of ovarian hyperstimulation syndrome – views and ideas. Hum Reprod. 1997;12:1129–37.CrossRef

Guzeloglu-Kayisli O, Kayisli U, Taylor H. The role of growth factors and cytokines during implantation: endocrine and paracrine interactions. Semin Reprod Med. 2009;27(1):62–79.CrossRef

Galvao AM, Ferreira-Dias G, Karzynski DS. Cytokines and angiogenesis in the corpus luteum. Hindawi Publishing Corporation. 2013; Article ID 420186, 11 doi: https://doi.org/10.1155/2013/420186 2013.

Field S, Dasgupta T, Cummings M, Orsi N. Cytokines in ovarian folliculogenesis, oocyte maturation and luteinisation. Mol Reprod Develop. 2014;81:284–314. https://doi.org/10.1002/mrd.22285.CrossRef

Orvieto R, Storobinsky O, Lantsberg D, Haas J, Mashich R, Cohen Y. Interlukien-2 and SOCS-1 proteins involvement in the pathophysiology of severe ovarian hyperstimulation syndrome- a preliminary proof of concept. J Ovarian Res. 2014;7(106):1–6. https://doi.org/10.1186/s13048-014-0106-2.CrossRef

10.

Shrestha D, La X, Feng HL. Comparison of different stimulation protocols used in in vitro fertilization: a review. Ann transl Med. 2015;3(10):137. https://doi.org/10.3978/j.issn.2305–5839.2015.04.09.

11.

Busso CE, Garcia-Velasco JA, Simon C, Pellicer A. Prevention of OHSS: current strategies and new insights. Middle East Soci J. 2010;15:223–30. https://doi.org/10.1016/j.mefs.2010.06.013.CrossRef

12.

Depalo R, Jayakrishan K, Garruti G, Totaro I, Panzario M, Giorgino F, et al. GnRH agonist versus GnRH antagonist in in vitro fertilization and embryo transfer (IVF/ET). Reprod Biol Endocrinol. 2012;10:26. https://doi.org/10.1186/1477-7827-10-26.CrossRefPubMedPubMedCentral

13.

Nastri CO, Teixeira DM, Moroni RM, Leitao VM, Martins WP. Ovarian hyperstimulation syndrome: pathophysiology, staging, prediction and prevention. Ultrasound in Obstet Gynecol. 2015;45(4):377–93. https://doi.org/10.1002/uog.14684.CrossRef

14.

Papanikolaou EG, Pozzobon C, Kolibianakis EM, Camus M, Tournaye H, Fatemi HM, et al. Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropin-releasing hormone antagonist in vitro fertilization cycles. Fertil Steril. 2006;85:112–20.CrossRef

15.

Alhilali M, Parham A, Attaranzadeh A, Amirian M, Azizzadeh M. IL-5 in follicular fluid as a negative predictor of the intracytoplasmic sperm injection outcome. Cytokine. 2019;113:265–71.CrossRef

16.

Griesinger G, Verweij PM, Gates D, Devroey P, Gordon K, Stegmann BJ, et al. Prediction of ovarian hyperstimulation syndrome in patients treated with corifollitropin alfa or rFSH in a GnRH antagonist protocol. Plos One. 2016:1–14. https://doi.org/10.1371/journal.pone.0149615.

17.

Agrawal R, Ling Tan S, Wild S, Sladkevicius P, Payne N, Engmann L, Bekir J, Campbell S, Conway G, Jacobs H. Serum vascular endothelial growth factor concentrations in in vitro fertilization cycles predict the risk of ovarian hyperstimulation syndrome. Fertil Steril. 1999;71:287–93.CrossRef

18.

Lee JR, Kim SH, Kim SM, Jee BC, Ku SY, Suh CS, Choi YM, Kim JG, Moon SY. Follicular fluid anti- Mullerian hormone and inhibin B concentrations: comparison between gonadotropin-releasing hormone (GnRH) agonist and GnRH antagonist cycles. Fertil Steril. 2008;89:860–7.CrossRef

19.

Chistyakova GN, Remizova II, Gazieva IA, Qhermyaninova OV. Immunological and hemostasiological disorders in women with ovarian hyperstimulation syndrome. Gynecol Endocrinol. 2014;30(S1):39–42. https://doi.org/10.3109/09513590.2014.945787.CrossRefPubMed

20.

Shi S, Peng Z, Yao G, Jin H, Song W, Yang H, et al. Expression of CD11c+HLA-DR+dendritic cells and related cytokines in the follicular fluid might be related to pathogenesis of ovarian hyperstimulation syndrome. Int J Clin Exp Pathol. 2015;8(11):15133–7.PubMedPubMedCentral

21.

Kilic S, Evsen M, Tasdemir N, Yuksel B, Dogan M, Batiloglu S. Follicular fluid vascular endothelial growth factor and tumor necrosis factor alpha concentrations in patients with endometriosis undergoing ICSI. Reprod BioMed Online. 2007;15:316–20.CrossRef

22.

Yamamoto Y, Kuwahara A, Taniguchi Y, Yamasaki M, Tanaka Y, Mukai Y, et al. Tumor necrosis factor alpha inhibits ovulation and induces granulosa cell death in rat ovaries. Reprod Med Biol. 2015;14:107–15. https://doi.org/10.1007/s12522-014-0201-5.CrossRefPubMed

23.

Artini PG, Monteleone P, Parsien Todin MR, Matteucci C, Ruggiero M, Cela V, et al. Growth factors and folliculogenesis in polycystic ovary patients. Expert Rev Edocrinol Metab. 2007;2(2):215–23.CrossRef

24.

Capaldo CT, Nusrat A. Cytokine regulation of tight junctions: A review. Biochemica et Biophysica Acta. 2009;1788:864–71. https://doi.org/10.1016/j.bbamen.2008.08.027.CrossRef

25.

Khil LY, Jun HS, Kown H, Yoo JK, Kim S, Notkin AL, et al. Human gonadotropin is an immune modulator and can prevent autoimmune diabetes in NOD mice. Diabetologia. 2007;50:2147–55.CrossRef

26.

Herr D, Bekes I, Wulff C. Regulation of endothelial permeability in the primate corpora lutea: implications for ovarian hyperstimulation syndrome. Reproduction. 2015;194:R71–9.CrossRef

27.

Drakopoulos P, Blockeel C, Stoop D, Camus M, deVos M, Tournaye H, et al. Conventional ovarian stimulation and single embryo transfer for IVF/ICSI. How many oocytes do we need to maximize cumulative live birth rates after utilization of all fresh and frozen embryos? Hum Reprod. 2016;31(2):370–6. https://doi.org/10.1093/humrep/dev316.CrossRefPubMed

28.

Revel A, Barak V, Lavy Y, Amit A, Finci-Yeheskel Z, Mayer M, et al. Characterization of intraperitoneal cytokines and nitrites in women with severe ovarian hyperstimulation syndrome. Fert Steril. 1996;66:66–71.CrossRef

29.

Kumar P, Sait SF, Sharma A, Kumar M. Ovarian hyperstimulation syndrome. J Hum Reprod Sci. 2011;4(2):70–5. https://doi.org/10.4103/0974-1208.86080.CrossRefPubMedPubMedCentral

30.

Soares SR. Go’mez R, Simo’n C, Garcı’a-Velasco JA, Pellicer a. targeting the vascular endothelial growth factor system to prevent ovarian hyperstimulation syndrome. Hum. Reprod. Update. 2008;14(4):321–33. https://doi.org/10.1093/humupd/dmn008.CrossRef

31.

Alper M, Fauser B. Ovarian stimulation protocols for IVF: is better than less? Reprod Biomed Online. 2017;34:345–53. https://doi.org/10.1016/j.rbmo.2017.01.010.CrossRefPubMed

32.

Shibahara H, Shimada K, Morimatsu Y, Kikuchi K, Hirano Y, Suzuki T. Severe ovarian hyperstimulation syndrome in a 42-year-old woman with successful pregnancy after intracytoplasmic sperm injection embryo transfer: case report. Reprod Med Bio. 2005;4:265–9. https://doi.org/10.1111/j.1447-0578.2005.00112.CrossRef

33.

Pandian Z, Bhattacharya S, Vale L, Templeton A. In vitro fertilisation for unexplained subfertility. Cochrane Database Syst Rev. 2015:CD003357. https://doi.org/10.1002/14651858.

Title: Prognostic role of follicular fluid tumor necrosis factor alpha in the risk of early ovarian hyperstimulation syndrome
Authors: Miaad Jabbar Alhilali
Abbas Parham
Armin Attaranzadeh
Malihe Amirian
Mohammad Azizzadeh
Publication date: 01-12-2020
Publisher: BioMed Central
Keywords: ICSI
Ovarian Hyperstimulation Syndrome
Cytokines
GnRH Agonists
Published in: BMC Pregnancy and Childbirth / Issue 1/2020
Electronic ISSN: 1471-2393
DOI: https://doi.org/10.1186/s12884-020-03379-9

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Prognostic role of follicular fluid tumor necrosis factor alpha in the risk of early ovarian hyperstimulation syndrome

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2020

Enhancing patient mobility following cesarean-delivery – the efficacy of an improved postpartum protocol assessed with pedometers

Maternal and newborn healthcare practices: assessment of the uptake of lifesaving services in Hoima District, Uganda

Prenatal prediction of neonatal haemodynamic adaptation after maternal hyperoxygenation

Prevalence and predictors of perceived disrespectful maternity care in postpartum Iranian women: a cross-sectional study

Prescribing antidepressants and anxiolytic medications to pregnant women: comparing perception of risk of foetal teratogenicity between Australian Obstetricians and Gynaecologists, Speciality Trainees and upskilled General Practitioners

Association of abnormal placental perfusion with the risk of male hypospadias: a hospital-based retrospective cohort study